Conclusion With a growing body of evidence supporting additional benefits and a continued rise in prescriptions for approved indications, GLP-1 therapies are poised to sustain strong growth in the years ahead
In terms of the primary outcome of reduction in A1C from baseline, although the 3-mg oral semaglutide group did not demonstrate superiority to sitagliptin 100 mg at 26 weeks, the 7-mg and 14-mg dosage groups did demonstrate statistically significant reductions in A1C from baseline when compared with sitagliptin
A bridge payment demonstration kicks off in July 2026, with beneficiaries paying just $50/month in copay
GLP-1 medications for weight loss are available through branded pharmaceutical manufacturers, telehealth platforms, traditional pharmacies, and licensed compounding facilities
They do not encourage people to skip meals in favour of less nutritionally beneficial foods like cake, nor do they encourage alcohol consumption in daily doses